bioRxiv is receiving many new papers on coronavirus SARS-CoV-2.   A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

10040 Articles (7896 medRxiv, 2144 bioRxiv)

Most recent first Previous |  Page 6: Articles 51-60  | Next

Development of Multiplexed RT-LAMP for Detection of SARS-CoV-2 and Influenza Viral RNA
Zhang, Y., Tanner, N. A.
10.1101/2020.10.26.20219972 — Posted: 2020-10-27
COVID-19 infections following outdoor mass gatherings in low incidence areas: retrospective cohort study
Miron, O., Yu, K.-H., Wilf-Miron, R., Davidovich, N.
10.1101/2020.10.22.20184630 — Posted: 2020-10-27
Hyper-Exponential Growth of COVID-19 during Resurgence of the Disease in Russia
Baruah, H. K.
10.1101/2020.10.26.20219626 — Posted: 2020-10-27
PREVALENCE OF MOLECULAR AND SEROLOGICAL TESTS OF THE NEW CORONAVIRUS (SARS-CoV-2) IN CARLOS CHAGAS-SABIN LABORATORIES IN CUIABA
de Paula, C. C., Passos, J. P. C., Bittencour, W. S., de Lamare, C. A. V., de Oliveira, R. G.
10.1101/2020.10.26.20219683 — Posted: 2020-10-27
Human movement can inform the spatial scale of interventions against COVID-19 transmission
Gibbs, H., Nightingale, E., Liu, Y., Cheshire, J., Danon, L., Smeeth, L., Pearson, C. A., Grundy, C., LSHTM CMMID COVID-19 Working Group, , Kucharski, A. J., Eggo, R. M.
10.1101/2020.10.26.20219550 — Posted: 2020-10-27
Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population
Arleo, T. L., Tong, D. C., Shabto, J. M., O'Keefe, G. D., Khosroshahi, A.
10.1101/2020.10.26.20219154 — Posted: 2020-10-27
Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India
Le Rutte, E. A., Coffeng, L. E., Munoz, J., de Vlas, S. J.
10.1101/2020.10.26.20219758 — Posted: 2020-10-27
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Yang, J.-K., Zhao, M.-M., Yang, W.-L., Yang, F.-Y., Zhang, L., Huang, W., Fan, C., Hou, W., Jin, R., Feng, Y., Wang, Y.
10.1101/2020.10.25.20218990 — Posted: 2020-10-27
Effects of New York's Executive Order on Face Mask Use on COVID-19 Infections and Mortality: A Modeling Study
Shen, M., Zu, J., Fairley, C. K., Pagan, J. A., Ferket, B., Liu, B., Yi, S. S., Chambers, E., Li, G., Guo, Y., Rong, L., Xiao, Y., Zhuang, G., Zebrowski, A., Carr, B. G., Li, Y., Zhang, L.
10.1101/2020.10.26.20219527 — Posted: 2020-10-27
What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley, J. I. D., Blok, D. J., Walker, M., Milton, P., Hopkins, A. D., Hamill, L. C., Downs, P., de Vlas, S. J., Stolk, W. A., Basanez, M.-G.
10.1101/2020.10.26.20219733 — Posted: 2020-10-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).